Compare
CASI Pharmaceuticals, Inc. vs Evofem Biosciences, Inc. vs Celularity Inc vs uniQure N.V.
| Latest fiscal year | CASI Pharmaceuticals, Inc. CASIF | Evofem Biosciences, Inc. EVFM | Celularity Inc CELU | uniQure N.V. QURE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $20.71M | $20.18M | $26.55M | $16.10M |
| Revenue growth (YoY) | -27.4% | +4.2% | -51.0% | -40.6% |
| Gross margin | 48.6% | 77.1% (computed) | 24.4% (computed) | 89.5% (computed) |
| Operating margin | -217.3% | 16.7% | -230.9% | n/m |
| Net margin | -232.0% | 1.9% | -345.4% | n/m |
| Net income | -$48.06M | $391.0K | -$91.72M | -$198.97M |
| EPS (Diluted) | -$2.59 | $0.00 | -$3.59 | -$3.46 |
| Operating cash flow | -$20.75M | -$1.99M | -$13.25M | -$177.96M |
| Free cash flow | -$20.77M | -$2.00M | n/a | -$178.40M |
| Cash & equivalents | $5.63M | $578.0K | $6.17M | $80.24M |
| Total assets | $25.65M | $20.27M | $107.33M | $824.91M |
| Total liabilities | $62.93M | $89.71M | $145.39M | $626.01M |
| Shareholders' equity | -$37.28M | -$74.34M | -$38.06M | $198.90M |
| Return on year-end equity | n/a | n/a | n/a | -100.0% |
| Shares outstanding | 20.56M | 126.69M | 28.84M | 62.34M |
Revenue, most recent five fiscal years
| Fiscal year | CASI Pharmaceuticals, Inc. | Evofem Biosciences, Inc. | Celularity Inc | uniQure N.V. |
|---|---|---|---|---|
| Latest | $20.71M Ended 2025-12-31 | $20.18M Ended 2025-12-31 | $26.55M Ended 2025-12-31 | $16.10M Ended 2025-12-31 |
| 1 year earlier | $28.54M Ended 2024-12-31 | $19.36M Ended 2024-12-31 | $54.22M Ended 2024-12-31 | $27.12M Ended 2024-12-31 |
| 2 years earlier | $33.88M Ended 2023-12-31 | $18.22M Ended 2023-12-31 | $22.77M Ended 2023-12-31 | $15.84M Ended 2023-12-31 |
| 3 years earlier | $43.11M Ended 2022-12-31 | $16.84M Ended 2022-12-31 | $17.98M Ended 2022-12-31 | $106.48M Ended 2022-12-31 |
| 4 years earlier | $30.17M Ended 2021-12-31 | $8.24M Ended 2021-12-31 | $21.34M Ended 2021-12-31 | $524.00M Ended 2021-12-31 |